Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Noncanonical agonist PPARγ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy.

Khandekar MJ, Banks AS, Laznik-Bogoslavski D, White JP, Choi JH, Kazak L, Lo JC, Cohen P, Wong KK, Kamenecka TM, Griffin PR, Spiegelman BM.

Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):561-566. doi: 10.1073/pnas.1717776115. Epub 2018 Jan 2.

PMID:
29295932
2.

The relationship between IGF2BP2 and PPARG polymorphisms and susceptibility to esophageal squamous-cell carcinomas in the eastern Chinese Han population.

Qiu H, Wang Y, Kang M, Ding H, Liu C, Tang W, Xiao Z, Chen Y.

Onco Targets Ther. 2017 Nov 21;10:5525-5532. doi: 10.2147/OTT.S145776. eCollection 2017.

3.

Biomarker correlation network in colorectal carcinoma by tumor anatomic location.

Nishihara R, Glass K, Mima K, Hamada T, Nowak JA, Qian ZR, Kraft P, Giovannucci EL, Fuchs CS, Chan AT, Quackenbush J, Ogino S, Onnela JP.

BMC Bioinformatics. 2017 Jun 17;18(1):304. doi: 10.1186/s12859-017-1718-5.

4.

Subcutaneous adiposity is an independent predictor of mortality in cancer patients.

Ebadi M, Martin L, Ghosh S, Field CJ, Lehner R, Baracos VE, Mazurak VC.

Br J Cancer. 2017 Jun 27;117(1):148-155. doi: 10.1038/bjc.2017.149. Epub 2017 Jun 6.

PMID:
28588319
5.

Musashi-1 promotes a cancer stem cell lineage and chemoresistance in colorectal cancer cells.

Chiou GY, Yang TW, Huang CC, Tang CY, Yen JY, Tsai MC, Chen HY, Fadhilah N, Lin CC, Jong YJ.

Sci Rep. 2017 May 19;7(1):2172. doi: 10.1038/s41598-017-02057-9.

6.

mRNA expression of nuclear factor of activated T-cells, cytoplasmic 2 (NFATc2) and peroxisome proliferator-activated receptor gamma (PPARG) transcription factors in colorectal carcinoma.

Zafari V, Hashemzadeh S, Hosseinpour Feizi M, Pouladi N, Rostami Zadeh L, Sakhinia E.

Bosn J Basic Med Sci. 2017 Aug 20;17(3):255-261. doi: 10.17305/bjbms.2017.1886.

7.

Fatty acid-binding protein 1 is preferentially lost in microsatellite instable colorectal carcinomas and is immune modulated via the interferon γ pathway.

Wood SM, Gill AJ, Brodsky AS, Lu S, Friedman K, Karashchuk G, Lombardo K, Yang D, Resnick MB.

Mod Pathol. 2017 Jan;30(1):123-133. doi: 10.1038/modpathol.2016.170. Epub 2016 Sep 30.

8.

Commonalities in the Association between PPARG and Vitamin D Related with Obesity and Carcinogenesis.

Bandera Merchan B, Tinahones FJ, Macías-González M.

PPAR Res. 2016;2016:2308249. doi: 10.1155/2016/2308249. Epub 2016 Aug 8. Review.

9.

Proteomic characterization of peroxisome proliferator-activated receptor-γ (PPARγ) overexpressing or silenced colorectal cancer cells unveils a novel protein network associated with an aggressive phenotype.

Milone MR, Pucci B, Colangelo T, Lombardi R, Iannelli F, Colantuoni V, Sabatino L, Budillon A.

Mol Oncol. 2016 Oct;10(8):1344-62. doi: 10.1016/j.molonc.2016.07.006. Epub 2016 Jul 25.

10.

Subcellular compartmentalization of docking protein-1 contributes to progression in colorectal cancer.

Friedrich T, Söhn M, Gutting T, Janssen KP, Behrens HM, Röcken C, Ebert MPA, Burgermeister E.

EBioMedicine. 2016 Jun;8:159-172. doi: 10.1016/j.ebiom.2016.05.003. Epub 2016 May 5.

11.

Lipidome in colorectal cancer.

Yan G, Li L, Zhu B, Li Y.

Oncotarget. 2016 May 31;7(22):33429-39. doi: 10.18632/oncotarget.7960. Review.

12.

Prognostic role of PPAR-γ and PTEN in the renal cell carcinoma.

Zhu C, Wei J, Tian X, Li Y, Li X.

Int J Clin Exp Pathol. 2015 Oct 1;8(10):12668-77. eCollection 2015.

13.

Clinical Significance of Peroxisome Proliferator-Activated Receptor γ and TRAP220 in Patients with Operable Colorectal Cancer.

Kwon KA, Yun J, Oh SY, Seo BG, Lee S, Lee JH, Kim SH, Choi HJ, Roh MS, Kim HJ.

Cancer Res Treat. 2016 Jan;48(1):198-207. doi: 10.4143/crt.2015.024. Epub 2015 Jun 23.

14.

The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells.

Ching J, Amiridis S, Stylli SS, Bjorksten AR, Kountouri N, Zheng T, Paradiso L, Luwor RB, Morokoff AP, O'Brien TJ, Kaye AH.

Oncotarget. 2015 Aug 28;6(25):21301-14.

15.

Chemotherapy and chemoprevention by thiazolidinediones.

Fröhlich E, Wahl R.

Biomed Res Int. 2015;2015:845340. doi: 10.1155/2015/845340. Epub 2015 Mar 19. Review.

16.

A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.

Sun LL, Wu JY, Wu ZY, Shen JH, Xu XE, Chen B, Wang SH, Li EM, Xu LY.

Int J Cancer. 2015 Mar 15;136(6):E569-77. doi: 10.1002/ijc.29211. Epub 2014 Sep 24.

17.

Colonic mucosal fatty acid synthase as an early biomarker for colorectal neoplasia: modulation by obesity and gender.

Cruz MD, Wali RK, Bianchi LK, Radosevich AJ, Crawford SE, Jepeal L, Goldberg MJ, Weinstein J, Momi N, Roy P, Calderwood AH, Backman V, Roy HK.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2413-21. doi: 10.1158/1055-9965.EPI-14-0026. Epub 2014 Aug 25.

18.

Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer.

Muc-Wierzgoń M, Nowakowska-Zajdel E, Dzięgielewska-Gęsiak S, Kokot T, Klakla K, Fatyga E, Grochowska-Niedworok E, Waniczek D, Wierzgoń J.

World J Gastroenterol. 2014 Aug 7;20(29):9759-74. doi: 10.3748/wjg.v20.i29.9759. Review.

19.

Emerging role of the β-catenin-PPARγ axis in the pathogenesis of colorectal cancer.

Sabatino L, Pancione M, Votino C, Colangelo T, Lupo A, Novellino E, Lavecchia A, Colantuoni V.

World J Gastroenterol. 2014 Jun 21;20(23):7137-51. doi: 10.3748/wjg.v20.i23.7137. Review.

20.

Chemopreventive drugs: mechanisms via inhibition of cancer stem cells in colorectal cancer.

Kim TI.

World J Gastroenterol. 2014 Apr 14;20(14):3835-46. doi: 10.3748/wjg.v20.i14.3835. Review.

Supplemental Content

Support Center